Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial

Ard van Veelen, Judith Gulikers,Lizza E.L. Hendriks,Safiye Dursun, Juanita Ippel,Egbert F. Smit,Anne-Marie C. Dingemans,Robin van Geel,Sander Croes

Lung Cancer（2022）

引用 6|浏览0

暂无评分

摘要

•Addition of cobicistat increased osimertinib exposure in all NSCLC patients.•Addition of cobicistat to osimertinib did not lead to unexpected or severe adverse events.•The osimertinib boosting effect of cobicistat was stable over time.

查看译文

关键词

Osimertinib,Cobicistat,Pharmacokinetic boosting,NSCLC,CYP3A4

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要